1313 related articles for article (PubMed ID: 27277623)
1. Implication of advanced glycation end products (Ages) and their receptor (Rage) on myocardial contractile and mitochondrial functions.
Neviere R; Yu Y; Wang L; Tessier F; Boulanger E
Glycoconj J; 2016 Aug; 33(4):607-17. PubMed ID: 27277623
[TBL] [Abstract][Full Text] [Related]
2. Aftermath of AGE-RAGE Cascade in the pathophysiology of cardiovascular ailments.
Wasim R; Mahmood T; Siddiqui MH; Ahsan F; Shamim A; Singh A; Shariq M; Parveen S
Life Sci; 2022 Oct; 307():120860. PubMed ID: 35940220
[TBL] [Abstract][Full Text] [Related]
3. Advanced glycation end products (AGEs) and cardiovascular dysfunction: focus on high molecular weight AGEs.
Deluyker D; Evens L; Bito V
Amino Acids; 2017 Sep; 49(9):1535-1541. PubMed ID: 28710551
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic Interventions for Advanced Glycation-End Products and its Receptor- Mediated Cardiovascular Disease.
Prasad K; Tiwari S
Curr Pharm Des; 2017; 23(6):937-943. PubMed ID: 27719648
[TBL] [Abstract][Full Text] [Related]
5. Phytochemicals Against Advanced Glycation End Products (AGEs) and the Receptor System.
Yamagishi SI; Matsui T; Ishibashi Y; Isami F; Abe Y; Sakaguchi T; Higashimoto Y
Curr Pharm Des; 2017; 23(8):1135-1141. PubMed ID: 27774900
[TBL] [Abstract][Full Text] [Related]
6. DNA-aptamers raised against AGEs as a blocker of various aging-related disorders.
Yamagishi S; Taguchi K; Fukami K
Glycoconj J; 2016 Aug; 33(4):683-90. PubMed ID: 27338620
[TBL] [Abstract][Full Text] [Related]
7. Assay for advanced glycation end products generating intracellular oxidative stress through binding to its receptor.
Kobori T; Ganesh D; Kumano-Kuramochi M; Torigoe K; Machida S
Anal Biochem; 2020 Dec; 611():114018. PubMed ID: 33186591
[TBL] [Abstract][Full Text] [Related]
8. Advanced Glycation End Products: A Molecular Target for Vascular Complications in Diabetes.
Yamagishi S; Nakamura N; Suematsu M; Kaseda K; Matsui T
Mol Med; 2015 Oct; 21 Suppl 1(Suppl 1):S32-40. PubMed ID: 26605646
[TBL] [Abstract][Full Text] [Related]
9. Advanced glycation end products and their receptor in age-related, non-communicable chronic inflammatory diseases; Overview of clinical evidence and potential contributions to disease.
Reynaert NL; Gopal P; Rutten EPA; Wouters EFM; Schalkwijk CG
Int J Biochem Cell Biol; 2016 Dec; 81(Pt B):403-418. PubMed ID: 27373680
[TBL] [Abstract][Full Text] [Related]
10. Impact of Advanced Glycation End products (AGEs) and its receptor (RAGE) on cancer metabolic signaling pathways and its progression.
Muthyalaiah YS; Jonnalagadda B; John CM; Arockiasamy S
Glycoconj J; 2021 Dec; 38(6):717-734. PubMed ID: 35064413
[TBL] [Abstract][Full Text] [Related]
11. Advanced Glycation End Products and Diabetes Mellitus: Mechanisms and Perspectives.
Khalid M; Petroianu G; Adem A
Biomolecules; 2022 Apr; 12(4):. PubMed ID: 35454131
[TBL] [Abstract][Full Text] [Related]
12. Advanced glycation end products (AGEs) and their involvement in liver disease.
Hyogo H; Yamagishi S
Curr Pharm Des; 2008; 14(10):969-72. PubMed ID: 18473847
[TBL] [Abstract][Full Text] [Related]
13. Pathological Role of Advanced Glycation End Products (AGEs) and their Receptor Axis in Atrial Fibrillation.
Yamagishi SI; Sotokawauchi A; Matsui T
Mini Rev Med Chem; 2019; 19(13):1040-1048. PubMed ID: 30854960
[TBL] [Abstract][Full Text] [Related]
14. Relationship of Advanced Glycation End Products With Cardiovascular Disease in Menopausal Women.
Pertynska-Marczewska M; Merhi Z
Reprod Sci; 2015 Jul; 22(7):774-82. PubMed ID: 25228634
[TBL] [Abstract][Full Text] [Related]
15. Activation of the receptor for advanced glycation end products and consequences on health.
Wautier MP; Guillausseau PJ; Wautier JL
Diabetes Metab Syndr; 2017; 11(4):305-309. PubMed ID: 27612394
[TBL] [Abstract][Full Text] [Related]
16. AGE-RAGE axis blockade in diabetic nephropathy: Current status and future directions.
Sanajou D; Ghorbani Haghjo A; Argani H; Aslani S
Eur J Pharmacol; 2018 Aug; 833():158-164. PubMed ID: 29883668
[TBL] [Abstract][Full Text] [Related]
17. A Glycation Angle to Look into the Diabetic Vasculopathy: Cause and Cure.
Ahmad S; Siddiqui Z; Rehman S; Khan MY; Khan H; Khanum S; Alouffi S; Saeed M
Curr Vasc Pharmacol; 2017; 15(4):352-364. PubMed ID: 28356033
[TBL] [Abstract][Full Text] [Related]
18. Crosstalk between advanced glycation end products (AGEs)-receptor RAGE axis and dipeptidyl peptidase-4-incretin system in diabetic vascular complications.
Yamagishi S; Fukami K; Matsui T
Cardiovasc Diabetol; 2015 Jan; 14():2. PubMed ID: 25582643
[TBL] [Abstract][Full Text] [Related]
19. Advanced glycation end products receptor RAGE controls myocardial dysfunction and oxidative stress in high-fat fed mice by sustaining mitochondrial dynamics and autophagy-lysosome pathway.
Yu Y; Wang L; Delguste F; Durand A; Guilbaud A; Rousselin C; Schmidt AM; Tessier F; Boulanger E; Neviere R
Free Radic Biol Med; 2017 Nov; 112():397-410. PubMed ID: 28826719
[TBL] [Abstract][Full Text] [Related]
20. Kinetics, role and therapeutic implications of endogenous soluble form of receptor for advanced glycation end products (sRAGE) in diabetes.
Yamagishi S; Matsui T; Nakamura K
Curr Drug Targets; 2007 Oct; 8(10):1138-43. PubMed ID: 17979674
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
